Moreover, given that our pathway analyses highlighted the involvement of the melanin metabolic and biosynthetic process in BCC pathogenesis, drugs targeting genes (i.e., TRPC1, SLC45A2, TYRP1, TYR, PMEL, DCT, OCA2, MYO5A, MC1R, CTNS, ASIP, DDT, and BCL2) involved in those pathways could be potential therapies for BCC. The gene discussed is BCL2; the disease is skin basal cell carcinoma.